Altered matrix metalloproteinases and tissue inhibitors of metalloproteinases in embryos from diabetic rats during early organogenesis

Reproductive Toxicology

Volumn 32, Issue 4, 2011, Pages 449-462

  Higa, Romina ^a   Kurtz, Melisa ^a   Capobianco, Evangelina ^a   Martínez, Nora ^a   White, Verónica ^a   Jawerbaum, Alicia ^a  

^a Centre de Estudios Farmacologicos y Botanicos   (Argentina)

Author keywords

Diabetes in pregnancy; Embryopathy; Matrix metalloproteinases (MMPs); Tissue inhibitor of metalloproteinases (TIMPs)

Indexed keywords

GELATINASE A; GELATINASE B; NITRIC OXIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DECIDUA; EMBRYO; EMBRYO DEVELOPMENT; EMBRYOPATHY; ENZYME ACTIVITY; ENZYME LOCALIZATION; FEMALE; IMMUNOLOCALIZATION; LIPID PEROXIDATION; MATERNAL DIABETES MELLITUS; NONHUMAN; ORGANOGENESIS; PROTEIN EXPRESSION; RAT;

ANIMALS; DECIDUA; DIABETES MELLITUS, EXPERIMENTAL; EMBRYO, MAMMALIAN; FEMALE; LIPID PEROXIDATION; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; NITRIC OXIDE; ORGANOGENESIS; PREGNANCY; PREGNANCY IN DIABETICS; RATS; RATS, WISTAR; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TISSUE INHIBITOR OF METALLOPROTEINASE-3; TISSUE INHIBITOR OF METALLOPROTEINASES;

ANIMALIA; RATTUS;

EID: 82155195873     PISSN: 08906238     EISSN: 18731708     Source Type: Journal    
DOI: 10.1016/j.reprotox.2011.09.003     Document Type: Article

References (63)

1. Sheffield J.S., Butler-Koster E.L., Casey B.M., McIntire D.D., Leveno K.J. Maternal diabetes mellitus and infant malformations. Obstet Gynecol 2002, 100:925-930.
2. Balsells M., Garcia-Patterson A., Gich I., Corcoy R. Maternal and fetal outcome in women with type 2 versus type 1 diabetes mellitus: a systematic review and metaanalysis. J Clin Endocrinol Metab 2009, 94:4284-4291.
3. Eriksson U.J. Congenital anomalies in diabetic pregnancy. Semin Fetal Neonatal Med 2009, 14:85-93.
4. Jensen D.M., Korsholm L., Ovesen P., Beck-Nielsen H., Moelsted-Pedersen L., Westergaard J.G., et al. Peri-conceptional A1C and risk of serious adverse pregnancy outcome in 933 women with type 1 diabetes. Diabetes Care 2009, 32:1046-1048.
5. Martinez-Frias M.L. Epidemiological analysis of outcomes of pregnancy in diabetic mothers: identification of the most characteristic and most frequent congenital anomalies. Am J Med Genet 1994, 51:108-113.
6. Eriksson U.J., Cederberg J., Wentzel P. Congenital malformations in offspring of diabetic mothers - animal and human studies. Rev Endocr Metab Disord 2003, 4:79-93.
7. Dheen S.T., Tay S.S., Boran J., Ting L.W., Kumar S.D., Fu J., et al. Recent studies on neural tube defects in embryos of diabetic pregnancy: an overview. Curr Med Chem 2009, 16:2345-2354.
8. Jawerbaum A., White V. Animal models in diabetes and pregnancy. Endocr Rev 2010, 31:680-701.
9. Jawerbaum A., Gonzalez E. The role of alterations in arachidonic acid metabolism and nitric oxide homeostasis in rat models of diabetes during early pregnancy. Curr Pharm Des 2005, 11:1327-1342.
10. Novaro V., Colman-Lerner A., Ortega F.V., Jawerbaum A., Paz D., Lo Nostro F., et al. Regulation of metalloproteinases by nitric oxide in human trophoblast cells in culture. Reprod Fertil Dev 2001, 13:411-420.
11. Pustovrh M.C., Jawerbaum A., White V., Capobianco E., Higa R., Martinez N., et al. The role of nitric oxide on matrix metalloproteinase 2 (MMP2) and MMP9 in placenta and fetus from diabetic rats. Reproduction 2007, 134:605-613.
12. Pustovrh M.C., Jawerbaum A., Capobianco E., White V., Martinez N., Lopez-Costa J.J., et al. Oxidative stress promotes the increase of matrix metalloproteinases-2 and -9 activities in the feto-placental unit of diabetic rats. Free Radic Res 2005, 39:1285-1293.
13. Page-McCaw A., Ewald A.J., Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 2007, 8:221-233.
14. Vu T.H., Werb Z. Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev 2000, 14:2123-2133.
15. Okamoto T., Niu R., Yamada S., Osawa M. Reduced expression of tissue inhibitor of metalloproteinase (TIMP)-2 in gestational trophoblastic diseases. Mol Hum Reprod 2002, 8:392-398.
16. Chow A.K., Cena J., Schulz R. Acute actions and novel targets of matrix metalloproteinases in the heart and vasculature. Br J Pharmacol 2007, 152:189-205.
17. Jawerbaum A., Gonzalez E. Diabetic pregnancies: the challenge of developing in a pro-inflammatory environment. Curr Med Chem 2006, 13:2127-2138.
18. Nagase H., Visse R., Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006, 69:562-573.
19. Ra H.J., Parks W.C. Control of matrix metalloproteinase catalytic activity. Matrix Biol 2007, 26:587-596.
20. Mandal M., Mandal A., Das S., Chakraborti T., Sajal C. Clinical implications of matrix metalloproteinases. Mol Cell Biochem 2003, 252:305-329.
21. Huang S.C., Sheu B.C., Chang W.C., Cheng C.Y., Wang P.H., Lin S. Extracellular matrix proteases - cytokine regulation role in cancer and pregnancy. Front Biosci 2009, 14:1571-1588.
22. Thrailkill K.M., Bunn R.C., Moreau C.S., Cockrell G.E., Simpson P.M., Coleman H.N., et al. Matrix metalloproteinase-2 dysregulation in type 1 diabetes. Diabetes Care 2007, 30:2321-2326.
23. Derosa G., D'Angelo A., Tinelli C., Devangelio E., Consoli A., Miccoli R., et al. Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in diabetic and healthy subjects. Diabetes Metab 2007, 33:129-134.
24. Pustovrh M.C., Jawerbaum A., Capobianco E., White V., Lopez-Costa J.J., Gonzalez E. Increased matrix metalloproteinases 2 and 9 in placenta of diabetic rats at midgestation. Placenta 2005, 26:339-348.
25. Pustovrh C., Jawerbaum A., Sinner D., Pesaresi M., Baier M., Micone P., et al. Membrane-type matrix metalloproteinase-9 activity in placental tissue from patients with pre-existing and gestational diabetes mellitus. Reprod Fertil Dev 2000, 12:269-275.
26. Pustovrh C., Jawerbaum A., Sinner D., White V., Capobianco E., Gonzalez E. Metalloproteinase 2 activity and modulation in uterus from neonatal streptozotocin-induced diabetic rats during embryo implantation. Reprod Fertil Dev 2002, 14:479-485.
27. Nuttall R.K., Kennedy T.G. Gelatinases A and B and tissue inhibitors of metalloproteinases 1, 2, and 3 during in vivo and in vitro decidualization of rat endometrial stromal cells. Biol Reprod 1999, 60:471-478.
28. Godbole G., Suman P., Gupta S.K., Modi D. Decidualized endometrial stromal cell derived factors promote trophoblast invasion. Fertil Steril 2011, 95:1278-1283.
29. Cohen M., Wuillemin C., Irion O., Bischof P. Role of decidua in trophoblastic invasion. Neuro Endocrinol Lett 2010, 31:193-197.
30. Parr E.L., Young L.H., Parr M.B., Young J.D. Granulated metrial gland cells of pregnant mouse uterus are natural killer-like cells that contain perforin and serine esterases. J Immunol 1990, 145:2365-2372.
31. Zygmunt M., Herr F., Munstedt K., Lang U., Liang O.D. Angiogenesis and vasculogenesis in pregnancy. Eur J Obstet Gynecol Reprod Biol 2003, 110(Suppl 1):S10-S18.
32. Giachini F.R., Carriel V., Capelo L.P., Tostes R.C., Carvalho M.H., Fortes Z.B., et al. Maternal diabetes affects specific extracellular matrix components during placentation. J Anat 2008, 212:31-41.
33. Caluwaerts S., Pijnenborg R., Luyten C., Van Assche F.A. Growth characteristics of diabetic rat ectoplacental cones in vivo and in vitro. Diabetologia 2000, 43:939-945.
34. Morgan S.C., Relaix F., Sandell L.L., Loeken M.R. Oxidative stress during diabetic pregnancy disrupts cardiac neural crest migration and causes outflow tract defects. Birth Defects Res A Clin Mol Teratol 2008, 82:453-463.
35. Wentzel P., Welsh N., Eriksson U.J. Developmental damage, increased lipid peroxidation, diminished cyclooxygenase-2 gene expression, and lowered prostaglandin E2 levels in rat embryos exposed to a diabetic environment. Diabetes 1999, 48:813-820.
36. Fassina G., Ferrari N., Brigati C., Benelli R., Santi L., Noonan D.M., et al. Tissue inhibitors of metalloproteases: regulation and biological activities. Clin Exp Metastasis 2000, 18:111-120.
37. Teesalu T., Masson R., Basset P., Blasi F., Talarico D. Expression of matrix metalloproteinases during murine chorioallantoic placenta maturation. Dev Dyn 1999, 214:248-258.
38. Das S.K., Yano S., Wang J., Edwards D.R., Nagase H., Dey S.K. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in the mouse uterus during the peri-implantation period. Dev Genet 1997, 21:44-54.
39. Naruse K., Lash G.E., Innes B.A., Otun H.A., Searle R.F., Robson S.C., et al. Localization of matrix metalloproteinase (MMP)-2, MMP-9 and tissue inhibitors for MMPs (TIMPs) in uterine natural killer cells in early human pregnancy. Hum Reprod 2009, 24:553-561.
40. Castro M.M., Rizzi E., Prado C.M., Rossi M.A., Tanus-Santos J.E., Gerlach R.F. Imbalance between matrix metalloproteinases and tissue inhibitor of metalloproteinases in hypertensive vascular remodeling. Matrix Biol 2010, 29:194-201.
41. Pustovrh M.C., Capobianco E., Martinez N., Higa R., White V., Jawerbaum A. MMP/TIMP balance is modulated in vitro by 15dPGJ(2) in fetuses and placentas from diabetic rats. Eur J Clin Invest 2009, 39:1082-1090.
42. Jawerbaum A., Higa R., White V., Capobianco E., Pustovrh C., Sinner D., et al. Peroxynitrites and impaired modulation of nitric oxide concentrations in embryos from diabetic rats during early organogenesis. Reproduction 2005, 130:695-703.
43. Ohkawa H., Ohishi N., Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979, 95:351-358.
44. Weiss A., Goldman S., Shalev E. The matrix metalloproteinases (MMPS) in the decidua and fetal membranes. Front Biosci 2007, 12:649-659.
45. Linask K.K., Han M., Cai D.H., Brauer P.R., Maisastry S.M. Cardiac morphogenesis: matrix metalloproteinase coordination of cellular mechanisms underlying heart tube formation and directionality of looping. Dev Dyn 2005, 233:739-753.
46. Ulrich R., Gerhauser I., Seeliger F., Baumgartner W., Alldinger S. Matrix metalloproteinases and their inhibitors in the developing mouse brain and spinal cord: a reverse transcription quantitative polymerase chain reaction study. Dev Neurosci 2005, 27:408-418.
47. Shum L., Sadler T.W. Embryonic catch-up growth after exposure to the ketone body d,l,-beta-hydroxybutyrate in vitro. Teratology 1988, 38:369-379.
48. Holmbeck K., Bianco P., Chrysovergis K., Yamada S., Birkedal-Hansen H. MT1-MMP-dependent, apoptotic remodeling of unmineralized cartilage: a critical process in skeletal growth. J Cell Biol 2003, 163:661-671.
49. Hiden U., Glitzner E., Ivanisevic M., Djelmis J., Wadsack C., Lang U., et al. MT1-MMP expression in first-trimester placental tissue is upregulated in type 1 diabetes as a result of elevated insulin and tumor necrosis factor-alpha levels. Diabetes 2008, 57:150-157.
50. Hu J., Van den Steen P.E., Sang Q.X., Opdenakker G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov 2007, 6:480-498.
51. He C. Molecular mechanism of transcriptional activation of human gelatinase B by proximal promoter. Cancer Lett 1996, 106:185-191.
52. Clark I.M., Swingler T.E., Sampieri C.L., Edwards D.R. The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol 2008, 40:1362-1378.
53. Wu L., Derynck R. Essential role of TGF-beta signaling in glucose-induced cell hypertrophy. Dev Cell 2009, 17:35-48.
54. Rajagopalan S., Meng X.P., Ramasamy S., Harrison D.G., Galis Z.S. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest 1996, 98:2572-2579.
55. Harris L.K., McCormick J., Cartwright J.E., Whitley G.S., Dash P.R. S-nitrosylation of proteins at the leading edge of migrating trophoblasts by inducible nitric oxide synthase promotes trophoblast invasion. Exp Cell Res 2008, 314:1765-1776.
56. Alexander C.M., Hansell E.J., Behrendtsen O., Flannery M.L., Kishnani N.S., Hawkes S.P., et al. Expression and function of matrix metalloproteinases and their inhibitors at the maternal-embryonic boundary during mouse embryo implantation. Development 1996, 122:1723-1736.
57. Stetler-Stevenson W.G. Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities. Sci Signal 2008, 1. re6.
58. Stilley J.A., Birt J.A., Nagel S.C., Sutovsky M., Sutovsky P., Sharpe-Timms K.L. Neutralizing TIMP1 restores fecundity in a rat model of endometriosis and treating control rats with TIMP1 causes anomalies in ovarian function and embryo development. Biol Reprod 2010, 83:185-194.
59. White V., Capobianco E., Higa R., Martinez N., Sosa M., Pustovrh M.C., et al. Increased nitration and diminished activity of copper/zinc superoxide dismutase in placentas from diabetic rats. Free Radic Res 2010, 44:1407-1415.
60. Yang Y., Candelario-Jalil E., Thompson J.F., Cuadrado E., Estrada E.Y., Rosell A., et al. Increased intranuclear matrix metalloproteinase activity in neurons interferes with oxidative DNA repair in focal cerebral ischemia. J Neurochem 2010, 112:134-149.
61. Fowell A.J., Collins J.E., Duncombe D.R., Pickering J.A., Rosenberg W.M., Benyon R.C. Silencing tissue inhibitors of metalloproteinases (TIMPs) with short interfering RNA reveals a role for TIMP-1 in hepatic stellate cell proliferation. Biochem Biophys Res Commun 2011, 407:277-282.
62. Zaltsman A.B., George S.J., Newby A.C. Increased secretion of tissue inhibitors of metalloproteinases 1 and 2 from the aortas of cholesterol fed rabbits partially counterbalances increased metalloproteinase activity. Arterioscler Thromb Vasc Biol 1999, 19:1700-1707.
63. Rosenberg G.A. Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurol 2009, 8:205-216.